Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.
Epistemonikos ID: 1cebf2c1365bc4718670e69e972f092b0b5cab71
First added on: Jan 01, 2021